1-(6-Methylpyridin-3-yl)-2-[4-(Methylsulfonyl)phenyl]ethanone CAS 221615-75-4 Etoricoxib Intermediate Purity >98.0% (HPLC)

Short Description:

1-(6-Methylpyridin-3-yl)-2-[4-(Methylsulfonyl)phenyl]ethanone

Synonyms: Etoricoxib Impurity D

CAS: 221615-75-4

Purity: >98.0% (HPLC)

Appearance: Pale Beige Powder

Intermediate of Etoricoxib (CAS: 202409-33-4)

Contact: Dr. Alvin Huang

Mobile/Wechat/WhatsApp: +86-15026746401

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

221615-75-4 - Description:

Ruifu Chemical is the leading manufacturer of 1-(6-Methylpyridin-3-yl)-2-[4-(Methylsulfonyl)phenyl]ethanone (CAS: 221615-75-4) with high quality, an intermediate in the synthesis of Etoricoxib (CAS: 202409-33-4).
Etoricoxib is widely used in the treatment of osteoarthritis (OA), acute gouty arthritis, and other diseases.
Ruifu Chemical has been supplying pharmaceutical intermediates and APIs more than 15 years. Ruifu Chemical can provide worldwide delivery, competitive price, excellent service, small and bulk quantities available. Purchase Etoricoxib intermediates or other pharmaceutical intermediates, Please contact: alvin@ruifuchem.com

Intermediates of Etoricoxib (CAS: 202409-33-4):

Etoricoxib API	CAS 202409-33-4
4-(Methylthio)phenylacetic Acid	CAS 16188-55-9
4-(Methylsulfonyl)phenylacetic Acid	CAS 90536-66-6
Methyl 6-Methylnicotinate	CAS 5470-70-2
1-(6-Methylpyridin-3-yl)-2-[4-(Methylthio)phenyl]ethanone	CAS 221615-72-1
1-(6-Methylpyridin-3-yl)-2-[4-(Methylsulfonyl)phenyl]ethanone	CAS 221615-75-4
2-Chloro-1,3-Bis(dimethylamino)trimethinium Hexafluorophosphate	CAS 249561-98-6 ; 291756-76-8

221615-75-4 - Chemical Properties:

Chemical Name	1-(6-Methylpyridin-3-yl)-2-[4-(Methylsulfonyl)phenyl]ethanone
Synonyms	1-(6-Methylpyridin-3-yl)-2-(4-(Methylsulfonyl)phenyl)ethan-1-one; 2-(4-Methanesulfonyl-phenyl)-1-(6-Methyl-Pyridin-3-yl)-Ethanone; 1-(6-Methyl-3-Pyridinyl)-2-[4-(Mmethylsulfonyl)phenyl]-Ethanone; Etoricoxib Intermediate 4; Etoricoxib Impurity D
Stock Status	In Stock, Commercial Production
CAS Number	221615-75-4
Molecular Formula	C15H15NO3S
Molecular Weight	289.35 g/mol
Melting Point	>169℃(dec.)
Density	1.242±0.06 g/cm3
Store Under Inert Gas	Store Under Inert Gas (Nitrogen or Argon) at 2~8℃
COA & MSDS	Available
Origin of Product	Shanghai, China
Product Categories	Pharmaceutical Intermediates
Brand	Ruifu Chemical

221615-75-4 - Specifications:

Items	Specifications	Results
Appearance	Pale Beige Powder	Pale Beige Powder
Loss on Drying	<1.00%	0.15%
Residue on Ignition	<0.50%	0.08%
Heavy Metals (Pb)	<20ppm	<20ppm
Purity / Analysis Method	>98.0% (HPLC)	99.3%
Infrared Spectrum	Consistent with Structure	Complies
NMR Spectrum	Consistent with Structure	Complies
Conclusion	The product has been tested and complies with the given specifications
Application	Intermediate of Etoricoxib (CAS: 202409-33-4)

221615-75-4 - Package/Storage/Shipping:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.
Storage Condition: Keep the container tightly closed and store in a cool, dry (2~8℃), well-ventilated warehouse away from incompatible substances. Keep away from sunshine; avoid fire and heat sources; avoid moisture.
Shipping: Deliver to worldwide by air, by FedEx / DHL Express. Provide fast and reliable delivery.

221615-75-4 - Advantages:

Sufficient Capacity: Sufficient facilities and technicians

Professional Service: One stop purchasing service

OEM Package: Custom package and label available

Fast Delivery: If within stock, three days delivery guaranteed

Stable Supply: Maintain reasonable stock

Technical Support: Technology solution available

Custom Synthesis Service: Ranged from grams to kilos

High Quality: Established a complete quality assurance system

221615-75-4 - FAQ:

How to Purchase? Please contact Dr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com

15 Years Experience? We have more than 15 years of experience in the manufacture and export of a wide range of high quality pharmaceutical intermediates or fine chemicals.

Main Markets? Sell to domestic market, North America, Europe, India, Korea, Japanese, Australia, etc.

Advantages? Superior quality, affordable price, professional services and technical support, fast delivery.

Quality Assurance? Strict quality control system. Professional equipment for analysis include NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, K.F, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, etc.

Samples? Most products provide free samples for quality evaluation, shipping cost should be paid by customers.

Factory Audit? Factory audit welcome. Please make an appointment in advance.

MOQ? No MOQ. Small order is acceptable.

Delivery Time? If within stock, three days delivery guaranteed.

Transportation? By Express (FedEx, DHL), by Air, by Sea.

Documents? After sales service: COA, MOA, ROS, MSDS, etc. can be provided.

Custom Synthesis? Can provide custom synthesis services to best fit your research needs.

Payment Terms? Proforma invoice will be sent first after confirmation of order, enclosed our bank information. Payment by T/T (Telex Transfer), PayPal, Western Union, etc.

221615-75-4 - Application:

1-(6-Methylpyridin-3-yl)-2-[4-(Methylsulfonyl)phenyl]ethanone (CAS: 221615-75-4) is an intermediate or impurity in the synthesis of Etoricoxib (CAS: 202409-33-4).
Etoricoxib is a kind of highly selective cyclooxygenase-2 (COX-2) inhibitors developed by the Merck company. Etoricoxib was first approved for entering into market in 2002 in the UK, followed by the marketing countries and regions including the European Union, Asia, Australia and Latin America. Until the end of 2013, it has been approved for marketing in 97 countries for being widely used in treatment of osteoarthritis (OA), rheumatoid arthritis, ankylosing spondylitis, chronic low back pain, acute gouty arthritis, primary dysmenorrhea and postoperative pain, and other diseases. Etoricoxib has also entered into market in Taiwan and Hong Kong of China. It had entered into market in Chinese mainland in 2008 with the approved indications being acute gouty arthritis and OA and another indication being primary dysmenorrhea in the second half year of 2014.